IFPMA wants 'holistic' debate on drug pricing

12 May 2017
drug_money_big

The World Health Organization (WHO) has held a forum on the cost of medicines in a stated attempt to facilitate discussion leading to ‘fairer price setting and a system that is sustainable for health systems and for innovation’.

Friday’s Fair Pricing Forum in Amsterdam was also a discussion about the ‘wanted but also unwanted consequences’ of the current drug development business model including ideas about possible alternative systems.

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), which represents research-based pharma companies across the globe, welcomed the opportunity to enhance innovation and increase patient access to medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical